The Latest Cardiac and Vascular News
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced its 510(k) submission for U.S. Food and Drug Administration (FDA) clearance of the AVANCE™ steerable introducer, designed for introducing various […]
SAN DIEGO and SAN CARLOS, Calif., Sept. 24, 2018 /PRNewswire/ — BioCardia®, Inc. (OTC :BCDA ), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that positive data from two studies of its investigational CardiAMP stem cell therapy were presented today […]
SAN CARLOS, Calif., Aug. 22, 2018 /PRNewswire/ — In a Viewpoint paper published online today in Circulation Research, the Phase III CardiAMP Heart Failure Trial (CardiAMP-HF Trial) studying the investigational CardiAMP stem cell therapyfrom BioCardia®, Inc. (OTC: BCDA) was highlighted as an example of personalized medicine, […]
SAN CARLOS, Calif., May 11, 2018 /PRNewswire/ — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, filed its 10-Q for the three months ended March 31, 2018 with the Securities and Exchange Commission. First Quarter 2018 Financial Results: […]
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved national reimbursement coverage for the CardiAMP Chronic Myocardial […]
SAN CARLOS, Calif., April 9, 2018 /PRNewswire/ — BioCardia®, Inc., [OTC: BCDA] a leader in cardiovascular regenerative medicine, today announced the publication of the Phase III CardiAMP Heart Failure Trial design paper in the American Heart Journal. Titled “The CardiAMP Heart Failure Trial: […]
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the FDA has approved an Investigational Device Exemption for the CardiAMP Chronic Myocardial Ischemia (CMI) Trial to treat patients with refractory […]
